Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Depreciation Expense (2019 - 2026)

Akebia Therapeutics has reported Depreciation Expense over the past 6 years, most recently at $321000.0 for Q4 2025.

  • Quarterly Depreciation Expense fell 4.18% to $321000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 13.2% year-over-year, with the annual reading at $1.3 million for FY2025, 13.2% down from the prior year.
  • Depreciation Expense was $321000.0 for Q4 2025 at Akebia Therapeutics, up from $318000.0 in the prior quarter.
  • Over five years, Depreciation Expense peaked at $408000.0 in Q4 2022 and troughed at $314000.0 in Q1 2025.
  • The 4-year median for Depreciation Expense is $364000.0 (2024), against an average of $363384.6.
  • Year-over-year, Depreciation Expense rose 0.76% in 2024 and then fell 21.0% in 2025.
  • A 4-year view of Depreciation Expense shows it stood at $408000.0 in 2022, then dropped by 3.43% to $394000.0 in 2023, then fell by 14.97% to $335000.0 in 2024, then dropped by 4.18% to $321000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Depreciation Expense are $321000.0 (Q4 2025), $318000.0 (Q3 2025), and $316000.0 (Q2 2025).